Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/56116
Title: Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study
Authors: 
Filiation: Servicio de Oncología Médica. Hospital Universitario de Fuenlabrada
Keywords: 
Mesh: 
Decs: 
Issue Date: 8-Nov-2022
Publisher: Springer Science and Business Media LLC
Citation: Yubero A, Barquín A, Estévez P, Pajares B, Sánchez L, Reche P, Alarcón J, Calzas J, Gaba L, Fuentes J, Santaballa A, Salvador C, Manso L, Herrero A, Taus Á, Márquez R, Madani J, Merino M, Marquina G, Casado V, Constenla M, Gutiérrez M, Dosil A, González-Martín A. Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study. BMC Cancer. 2022 Nov 8;22(1):1150. doi: 10.1186/s12885-022-10191-5. PMID: 36348385.
Abstract: Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for recurrent platinum-sensitive (Pt-S) ovarian cancer (OC). The Rucaparib Access Programme (RAP) was designed to provide early access to rucaparib for the above-mentioned indication, as well as for patients with BRCA-mutated Pt-S or platinum-resistant (Pt-R) OC and no therapeutic alternatives.
PMID: 36348385
URI: https://hdl.handle.net/20.500.12530/56116
Rights: info:eu-repo/semantics/openAccess
Atribución 3.0 España
ISSN: 1471-2407
Appears in Collections:Hospitales > H. U. de Fuenlabrada > Artículos

Files in This Item:
File Description SizeFormat 
BMC Cancer.pdf1.42 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons